Frederick S Kaplan

List of Publications by Year
in descending order

200	13,267	19657 61	24982 109
papers	citations	h-index	g-index

208	208	208	6338
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics, 2006, 38, 525-527.	21.4	1,079
2	Bone Formation and Inflammation in Cardiac Valves. Circulation, 2001, 103, 1522-1528.	1.6	922
3	Conversion of vascular endothelial cells into multipotent stem-like cells. Nature Medicine, 2010, 16, 1400-1406.	30.7	635
4	Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva. New England Journal of Medicine, 1996, 335, 555-561.	27.0	364
5	Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Human Mutation, 2009, 30, 379-390.	2.5	364
6	Fibrodysplasia ossificans progressiva. Best Practice and Research in Clinical Rheumatology, 2008, 22, 191-205.	3.3	310
7	Heterotopic Ossification. Journal of the American Academy of Orthopaedic Surgeons, The, 2004, 12, 116-125.	2.5	307
8	Paternally Inherited Inactivating Mutations of theGNAS1Gene in Progressive Osseous Heteroplasia. New England Journal of Medicine, 2002, 346, 99-106.	27.0	284
9	Identification of Progenitor Cells That Contribute to Heterotopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2009, 91, 652-663.	3.0	278
10	Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects. Orphanet Journal of Rare Diseases, 2011, 6, 80.	2.7	231
11	Inherited human diseases of heterotopic bone formation. Nature Reviews Rheumatology, 2010, 6, 518-527.	8.0	220
12	Iatrogenic Harm Caused by Diagnostic Errors in Fibrodysplasia Ossificans Progressiva. Pediatrics, 2005, 116, e654-e661.	2.1	203
13	Progressive Osseous Heteroplasia. Journal of Bone and Mineral Research, 2000, 15, 2084-2094.	2.8	192
14	Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification. Nature Medicine, 2013, 19, 1505-1512.	30.7	187
15	Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva. Journal of Biological Chemistry, 2009, 284, 7149-7156.	3.4	184
16	Age-related changes in proprioception and sensation of joint position. Acta Orthopaedica, 1985, 56, 72-74.	1.4	181
17	The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. Journal of Clinical Investigation, 2009, 119, 3462-72.	8.2	178
18	Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2010, 92, 686-691.	3.0	169

#	Article	IF	Citations
19	An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. Journal of Bone and Mineral Research, 2012, 27, 1746-1756.	2.8	157
20	The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. Journal of Bone and Mineral Research, 2016, 31, 650-656.	2.8	157
21	Early Diagnosis of Fibrodysplasia Ossificans Progressiva. Pediatrics, 2008, 121, e1295-e1300.	2.1	151
22	Heparan Sulfate Proteoglycans (HSPGs) Modulate BMP2 Osteogenic Bioactivity in C2C12 Cells. Journal of Biological Chemistry, 2007, 282, 1080-1086.	3.4	143
23	Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Journal of Bone and Mineral Research, 2016, 31, 1666-1675.	2.8	137
24	Dysregulated BMP Signaling and Enhanced Osteogenic Differentiation of Connective Tissue Progenitor Cells From Patients With Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 2008, 23, 305-313.	2.8	135
25	IN VIVO SOMATIC CELL GENE TRANSFER OF AN ENGINEERED NOGGIN MUTEIN PREVENTS BMP4-INDUCED HETEROTOPIC OSSIFICATION. Journal of Bone and Joint Surgery - Series A, 2003, 85, 2332-2342.	3.0	128
26	Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva. Journal of Bone and Mineral Research, 2018, 33, 269-282.	2.8	118
27	Fibrodysplasia ossificans progressiva: A clue from the fly?. Calcified Tissue International, 1990, 47, 117-125.	3.1	117
28	Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone, 2008, 43, 427-433.	2.9	117
29	Bone morphogenetic protein 24 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Human Pathology, 1997, 28, 339-343.	2.0	115
30	Deficiency of the Î±-Subunit of the Stimulatory G Protein and Severe Extraskeletal Ossification. Journal of Bone and Mineral Research, 2000, 15, 2074-2083.	2.8	110
31	Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. Journal of Bone and Mineral Research, 2016, 31, 1652-1665.	2.8	110
32	Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. DMM Disease Models and Mechanisms, 2012, 5, 756-762.	2.4	109
33	Fibrodysplasia ossificans progressiva. Pediatric Radiology, 2001, 31, 307-314.	2.0	108
34	Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. Journal of Pediatrics, 1995, 126, 762-764.	1.8	104
35	Fibrodysplasia Ossificans Progressiva (FOP), a Disorder of Ectopic Osteogenesis, Misregulates Cell Surface Expression and Trafficking of BMPRIA. Journal of Bone and Mineral Research, 2005, 20, 1168-1176.	2.8	103
36	Hematopoietic Stem-Cell Contribution to Ectopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2007, 89, 347-357.	3.0	102

#	Article	IF	Citations
37	Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1996, 81, 21-25.	1.4	99
38	Substance P signaling mediates BMP-dependent heterotopic ossification. Journal of Cellular Biochemistry, 2011, 112, 2759-2772.	2.6	99
39	The Genetics of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 201-204.	0.8	98
40	Dysregulation of the BMP-p38 MAPK Signaling Pathway in Cells From Patients With Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 2006, 21, 902-909.	2.8	97
41	Acute Lymphocytic Infiltration in an Extremely Early Lesion of Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 19???25.	1.5	96
42	Mast cell involvement in fibrodysplasia ossificans progressiva. Human Pathology, 2001, 32, 842-848.	2.0	96
43	The Phenotype of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 183-188.	0.8	94
44	Alk2 Regulates Early Chondrogenic Fate in Fibrodysplasia Ossificans Progressiva Heterotopic Endochondral Ossification. Stem Cells, 2014, 32, 1289-1300.	3.2	94
45	Developmental Anomalies of the Cervical Spine in Patients With Fibrodysplasia Ossificans Progressiva Are Distinctly Different From Those in Patients With Klippel-Feil Syndrome. Spine, 2005, 30, 1379-1385.	2.0	89
46	Fibrodysplasia Ossificans Progressiva, a Heritable Disorder of Severe Heterotopic Ossification, Maps to Human Chromosome 4q27-31*. American Journal of Human Genetics, 2000, 66, 128-135.	6.2	88
47	Functional Modeling of the ACVR1 (R206H) Mutation in FOP. Clinical Orthopaedics and Related Research, 2007, 462, 87-92.	1.5	86
48	Age- and Joint-Specific Risk of Initial Heterotopic Ossification in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1994, &NA;, 243???248.	1.5	84
49	Hematopoietic Stem-Cell Contribution to Ectopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2007, 89, 347-357.	3.0	81
50	PARESIS OF A BONE MORPHOGENETIC PROTEIN-ANTAGONIST RESPONSE IN A GENETIC DISORDER OF HETEROTOPIC SKELETOGENESIS. Journal of Bone and Joint Surgery - Series A, 2003, 85, 667-674.	3.0	79
51	Heterotopic Ossification: Two Rare Forms and What They Can Teach Us. Journal of the American Academy of Orthopaedic Surgeons, The, 1994, 2, 288-296.	2.5	78
52	Bone morphogenetic protein: Chromosomal localization of human genes for BMP1, BMP2A, and BMP3. Genomics, 1991, 9, 283-289.	2.9	77
53	Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). Journal of Bone and Mineral Metabolism, 2008, 26, 521-530.	2.7	73
54	Proximal Tibial Osteochondromas in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2008, 90, 366-374.	3.0	71

#	Article	IF	Citations
55	Influenza-like Viral Illnesses and Flare-ups of Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2004, 423, 275-279.	1.5	68
56	Heterozygous inactivation of Gnas in adipose-derived mesenchymal progenitor cells enhances osteoblast differentiation and promotes heterotopic ossification. Journal of Bone and Mineral Research, 2011, 26, 2647-2655.	2.8	68
57	Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. The Application of Clinical Genetics, 2015, 8, 37.	3.0	67
58	GNAS1 Mutation and Cbfa1 Misexpression in a Child with Severe Congenital Platelike Osteoma Cutis. Journal of Bone and Mineral Research, 2000, 15, 2063-2073.	2.8	66
59	The Immunological Contribution to Heterotopic Ossification Disorders. Current Osteoporosis Reports, 2015, 13, 116-124.	3.6	66
60	The Fibrodysplasia Ossificans Progressiva Lesion. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 195-200.	0.8	65
61	Dysregulation of the BMP-4 Signaling Pathway in Fibrodysplasia Ossificans Progressiva. Annals of the New York Academy of Sciences, 2006, 1068, 54-65.	3.8	65
62	In vitro Analyses of the Dysregulated R206H ALK2 Kinase-FKBP12 Interaction Associated with Heterotopic Ossification in FOP. Cells Tissues Organs, 2011, 194, 291-295.	2.3	65
63	Thoracic Insufficiency Syndrome in Patients With Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 213-216.	0.8	63
64	The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine and Growth Factor Reviews, 2009, 20, 399-407.	7.2	60
65	Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification?. Journal of Pathology, 2003, 201, 141-148.	4.5	59
66	Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 437-48.	1.2	59
67	The phenotype and genotype of fibrodysplasia ossificans progressiva in China: A report of 72 cases. Bone, 2013, 57, 386-391.	2.9	56
68	Pulmonary and Cardiac Function in Advanced Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 104???109.	1.5	54
69	Granting immunity to FOP and catching heterotopic ossification in the Act. Seminars in Cell and Developmental Biology, 2016, 49, 30-36.	5.0	54
70	A bone morphogenetic protein subfamily: Chromosomal localization of human genes for BMP5, BMP6, and BMP7. Genomics, 1992, 14, 759-762.	2.9	52
71	Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet Journal of Rare Diseases, 2019, 14, 98.	2.7	51
72	A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opinion on Biological Therapy, 2007, 7, 705-712.	3.1	50

#	Article	IF	Citations
73	Catastrophic Falls in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 110???116.	1.5	48
74	ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Human Molecular Genetics, 2014, 23, 5364-5377.	2.9	48
75	Conductive Hearing Loss in Individuals with Fibrodysplasia Ossificans Progressiva. American Journal of Audiology, 1999, 8, 29-33.	1.2	47
76	Immunological Features of Fibrodysplasia Ossificans Progressiva and the Dysregulated BMP4 Pathway. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 189-194.	0.8	45
77	Somitic disruption of GNAS in chick embryos mimics progressive osseous heteroplasia. Journal of Clinical Investigation, 2013, 123, 3624-3633.	8.2	45
78	Bone Morphogenetic Protein-4 Regulation in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2003, 408, 331-343.	1.5	43
79	Morphogen Receptor Genes and Metamorphogenes: Skeleton Keys to Metamorphosis. Annals of the New York Academy of Sciences, 2007, 1116, 113-133.	3.8	42
80	The role of morphogens in endochondral ossification. Calcified Tissue International, 1992, 50, 283-289.	3.1	41
81	Three Pairs of Monozygotic Twins With Fibrodysplasia Ossificans Progressiva: <I>The Role of Environment in the Progression of Heterotopic Ossification</I>. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 205-208.	0.8	41
82	A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone, 2017, 101, 123-128.	2.9	41
83	Treatment Considerations for the Management of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 243-250.	0.8	39
84	Neurological symptoms in individuals with fibrodysplasia ossificans progressiva. Journal of Neurology, 2012, 259, 2636-2643.	3.6	39
85	The face signature of fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2012, 158A, 1368-1380.	1.2	38
86	Observer variation in the detection of osteopenia. Skeletal Radiology, 1986, 15, 347-349.	2.0	37
87	Treatment of Patients Who Have Fibrodysplasia Ossificans Progressiva With Isotretinoin. Clinical Orthopaedics and Related Research, 1998, 346, 121???129.	1.5	37
88	CNS demyelination in fibrodysplasia ossificans progressiva. Journal of Neurology, 2012, 259, 2644-2655.	3.6	37
89	Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 218-224.	2.9	36
90	Vascular ossification: Pathology, mechanisms, and clinical implications. Bone, 2018, 109, 28-34.	2.9	35

#	Article	IF	Citations
91	From mysteries to medicines: drug development for fibrodysplasia ossificans progressiva. Expert Opinion on Orphan Drugs, 2013, 1, 637-649.	0.8	34
92	Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opinion on Orphan Drugs, 2017, 5, 291-294.	0.8	34
93	Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. Bone, 2018, 109, 276-280.	2.9	34
94	Multiâ€system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2265-2271.	1.2	33
95	Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Annals of the New York Academy of Sciences, 2011, 1237, 5-10.	3.8	31
96	Progressive osseous heteroplasia-like heterotopic ossification in a male infant with pseudohypoparathyroidism type Ia: A case report. Bone, 2007, 40, 1425-1428.	2.9	30
97	Role of Altered Signal Transduction in Heterotopic Ossification and Fibrodysplasia Ossificans Progressiva. Current Osteoporosis Reports, 2011, 9, 83-88.	3.6	30
98	General Anesthesia for Dental Procedures in Patients with Fibrodysplasia Ossificans Progressiva. Anesthesia and Analgesia, 2014, 118, 298-301.	2.2	30
99	Encrypted morphogens of skeletogenesis. Biochemical Pharmacology, 1998, 55, 373-382.	4.4	29
100	Fibrodysplasia ossificans progressiva in two half-sisters: Evidence for maternal mosaicism. , 1996, 61, 320-324.		28
101	Fibrodysplasia ossificans progressiva (FOP): watch the great toes!. European Journal of Pediatrics, 2010, 169, 1417-1421.	2.7	28
102	Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome. Frontiers in Endocrinology, 2019, 10, 908.	3.5	28
103	Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet Journal of Rare Diseases, 2021, 16, 350.	2.7	28
104	Limb Swelling in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1997, 336, 247-253.	1.5	26
105	Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis. Bone, 2020, 140, 115539.	2.9	26
106	Skin and Bones. Archives of Dermatology, 1996, 132, 815.	1.4	25
107	Epidemiology of the Global Fibrodysplasia Ossificans Progressiva (FOP) Community. Journal of Rare Diseases Research & Treatment, 2020, 5, 31-36.	1.1	25
108	Characterization of Bone Morphogenetic Protein 4 Receptor in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 38???45.	1.5	24

#	Article	IF	Citations
109	Oral and Dental Health Care and Anesthesia for Persons With Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 239-242.	0.8	24
110	Chin-on-Chest Deformity in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2009, 91, 1497-1502.	3.0	24
111	Paternally Inherited GsÎ± Mutation Impairs Adipogenesis and Potentiates a Lean Phenotype In Vivo. Stem Cells, 2012, 30, 1477-1485.	3.2	24
112	GsÎ± Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and Î²-Catenin Pathways. Scientific Reports, 2017, 7, 45140.	3.3	24
113	Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 259-266.	2.9	24
114	Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva. Bone, 2020, 130, 115116.	2.9	22
115	Clinical staging of Fibrodysplasia Ossificans Progressiva (FOP). Bone, 2018, 109, 111-114.	2.9	21
116	Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 1997, 12, 855-855.	2.8	20
117	Fibrodysplasia Ossificans Progressiva. , 0, , 827-840.		20
118	Progressive osseous heteroplasia in the face of a child. American Journal of Medical Genetics Part A, 2003, 118A, 71-75.	2.4	20
119	Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable. Bone, 2018, 109, 147-152.	2.9	20
120	Traumatic Fractures of Heterotopic Bone in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1994, &NA;, 173???177.	1.5	19
121	Derailing heterotopic ossification and RARing to go. Nature Medicine, 2011, 17, 420-421.	30.7	19
122	Osteochondral Diseases and Fibrodysplasia Ossificans Progressiva. Advances in Experimental Medicine and Biology, 2010, 686, 335-348.	1.6	19
123	The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva. Bone, 2018, 109, 285-290.	2.9	19
124	HSPG modulation of BMP signaling in fibrodysplasia ossificans progressiva cells. Journal of Cellular Biochemistry, 2007, 102, 1493-1503.	2.6	18
125	When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP). Drug Discovery Today: Therapeutic Strategies, 2008, 5, 255-262.	0.5	18
126	ECSIT links TLR and BMP signaling in FOP connective tissue progenitor cells. Bone, 2018, 109, 201-209.	2.9	18

#	Article	IF	Citations
127	Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva. Bone, 2018, 109, 104-110.	2.9	18
128	Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases. Bone, 2018, 109, 281-284.	2.9	18
129	Urinary Basic Fibroblast Growth Factor. Clinical Orthopaedics and Related Research, 1998, 346, 59???65.	1.5	17
130	Over-expression ofBMP4 andBMP5 in a child with axial skeletal malformations and heterotopic ossification: A new syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 699-706.	1.2	17
131	Lumbar puncture and surgical intervention in a child with undiagnosed fibrodysplasia ossificans progressiva. Journal of Neurosurgery: Pediatrics, 2008, 1, 91-94.	1.3	17
132	Investigations of Activated ACVR1/ALK2, a Bone Morphogenetic Protein Type I Receptor, That Causes Fibrodysplasia Ossificans Progressiva. Methods in Enzymology, 2010, 484, 357-373.	1.0	16
133	ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva. Bone, 2016, 92, 29-36.	2.9	15
134	International physician survey on management of FOP: a modified Delphi study. Orphanet Journal of Rare Diseases, 2017, 12, 110.	2.7	15
135	Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Frontiers in Endocrinology, 2021, 12, 732728.	3.5	15
136	Reported noggin mutations are PCR errors. American Journal of Medical Genetics Part A, 2002, 109, 161-161.	2.4	14
137	Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 124-133.	2.9	14
138	Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 115-119.	2.9	14
139	Fibrodysplasia Ossificans Progressiva and Progressive Osseous Heteroplasia: <I>Two Genetic Disorders of Heterotopic Ossification</I>. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 257-260.	0.8	13
140	Druggable targets, clinical trial design and proposed pharmacological management in fibrodysplasia ossificans progressiva. Expert Opinion on Orphan Drugs, 2020, 8, 101-109.	0.8	12
141	Animal Models of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 229-234.	0.8	11
142	Fibrodysplasia Ossificans Progressiva: An Historical Perspective. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 179-182.	0.8	9
143	The skeleton in the closet. Gene, 2013, 528, 7-11.	2.2	9
144	The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call. European Journal of Medical Genetics, 2017, 60, 399-402.	1.3	9

#	Article	IF	Citations
145	Ablation of GsÎ± signaling in osteoclast progenitor cells adversely affects skeletal bone maintenance. Bone, 2018, 109, 86-90.	2.9	9
146	Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 158-161.	2.9	9
147	Prevalence and risk factors for kidney stones in fibrodysplasia ossificans progressiva. Bone, 2018, 109, 120-123.	2.9	9
148	The Developmental Phenotype of the Great Toe in Fibrodysplasia Ossificans Progressiva. Frontiers in Cell and Developmental Biology, 2020, 8, 612853.	3.7	9
149	The Craniofacial Phenotype of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 209-212.	0.8	8
150	Dysregulation of BMP4 Receptor Trafficking and Signaling in Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 217-224.	0.8	8
151	Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva. Academic Radiology, 2017, 24, 321-327.	2.5	8
152	Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 153-157.	2.9	8
153	Patients with ACVR1R206H mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of Fibrodysplasia Ossificans Progressiva. Orphanet Journal of Rare Diseases, 2020, 15, 193.	2.7	8
154	Fibrodysplasia Ossificans Progressiva: Developmental Implications of a Novel Metamorphogene. , 2010, , 233-249.		8
155	Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP). Developmental Biology, 2021, 470, 136-146.	2.0	7
156	Embryonic Overexpression of the c-Fos Protooncogene. Clinical Orthopaedics and Related Research, 1998, 346, 81???94.	1.5	6
157	Exoneration of NF-??B Dysregulation in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2003, 406, 205-213.	1.5	6
158	Severe soft tissue ossification in a southern right whale Eubalaena australis. Diseases of Aquatic Organisms, 2012, 102, 149-156.	1.0	6
159	A case report of mesenteric heterotopic ossification: Histopathologic and genetic findings. Bone, 2018, 109, 56-60.	2.9	6
160	Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva. Bone, 2021, 150, 116016.	2.9	6
161	Clearance of Senescent Cells From Injured Muscle Abrogates Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva. Journal of Bone and Mineral Research, 2020, 37, 95-107.	2.8	6
162	Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective. Orphanet Journal of Rare Diseases, 2022, 17, 168.	2.7	6

#	Article	IF	Citations
163	Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles. Human Gene Therapy, 2022, 33, 782-788.	2.7	6
164	Pregnancy in fibrodysplasia ossificans progressiva. Obstetric Medicine, 2012, 5, 35-38.	1.1	5
165	Fibrodysplasia (Myositis) Ossificans Progressiva. , 2013, , 375-393.		5
166	Severe digital malformations in a rare variant of fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2019, 179, 1310-1314.	1.2	5
167	Whole-body Computed Tomography Versus Dual Energy Xâ€'ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva. Calcified Tissue International, 2021, 109, 615-625.	3.1	5
168	Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States. Journal of Bone and Mineral Research, 2020, 37, 475-483.	2.8	4
169	Orthopedic Surgery Considerations in Paget's Disease of Bone. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 159-166.	0.8	3
170	Garetosmab Reduces Flare-ups in Patients With Fibrodysplasia Ossificans Progressiva. Journal of the Endocrine Society, 2021, 5, A251-A252.	0.2	3
171	An ACVR1 R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2021, , .	1.2	3
172	Heterotopic Ossification in the Mesentery After Abdominal Surgery. , 2006, 16, 323-328.		2
173	Focal Fibronodular Heterotopic Ossification. Journal of Bone and Joint Surgery - Series A, 2007, 89, 1329-1336.	3.0	2
174	Functional Analysis of Alleged NOGGIN Mutation G92E Disproves Its Pathogenic Relevance. PLoS ONE, 2012, 7, e35062.	2.5	2
175	Fibrodysplasia (Myositis) Ossificans Progressiva. , 2018, , 523-545.		2
176	Cover Image, Volume 179A, Number 7, July 2019. , 2019, 179, .		2
177	Focal Fibronodular Heterotopic Ossification. Journal of Bone and Joint Surgery - Series A, 2007, 89, 1329-1336.	3.0	2
178	Surgical and Radiological Management of Complicated Uterine Leiomyoma Aided by 3D Models in a Patient with Fibrodysplasia Ossificans Progressiva. American Journal of Case Reports, 2021, 22, e931614.	0.8	1
179	<scp>Nonclassic</scp> fibrodysplasia ossificans progressiva: A child from Angola with an <scp>ACVR1^{G328E}</scp> variant. American Journal of Medical Genetics, Part A, 2021, 185, 2572-2575.	1.2	1
180	Chapter 94. Fibrodysplasia (Myositis) Ossificans Progressiva. , 0, , 442-446.		1

#	Article	IF	Citations
181	Fibrodysplasia Ossificans Progressiva (FOP): The Value of Studying a Rare Disorder. Drug Information Journal, 1997, 31, 273-277.	0.5	0
182	â€œYour Pal, Johnâ€• Calcified Tissue International, 1997, 61, 261-262.	3.1	0
183	Early Fibrodysplasia Ossificans Progressiva-Like Lesion Formation in Nude Mice Following Implantation of Lymphoblastoid Cells From FOP Patients. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 225-228.	0.8	0
184	Key to the kingdom: the challenge of rare diseases. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 233-235.	0.5	0
185	Viewing FOP through rosi-colored glasses. Journal of Bone and Mineral Research, 2010, 25, 2295-2296.	2.8	0
186	The complex craniofacial signature of fibrodysplasia ossificans progressiva: Whose handwriting is it?. American Journal of Medical Genetics, Part A, 2012, 158A, 2979-2980.	1.2	0
187	Extraskeletal Bone Formation. , 2012, , 821-840.		0
188	BMP Signaling in Fibrodysplasia Ossificans Progressiva, a Rare Genetic Disorder of Heterotopic Ossification. , 2017, , 327-343.		0
189	Reply to: Macrophages Driving Heterotopic Ossification: Convergence of Genetically-Driven and Trauma-Driven Mechanisms. Journal of Bone and Mineral Research, 2018, 33, 367-368.	2.8	0
190	Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients. Bone, 2021, 149, 115978.	2.9	0
191	Fibrodysplasia Ossificans Progressiva. , 2000, , 211-236.		0
192	ACVR1 and Fibrodysplasia Ossificans Progressiva. , 2016, , 435-438.		0
193	Fibrodysplasia ossificans progressiva: baseline characteristics of 101 subjects participating in a global, longitudinal, natural history study. Bone Abstracts, 0, , .	0.0	0
194	SUN-344 Patients with Fibrodysplasia Ossificans Progressiva Have an Increased Prevalence of Cardiac Conduction Abnormalities. Journal of the Endocrine Society, 2020, 4, .	0.2	0
195	Fibrodysplasia Ossificans Progressiva in Three Filipino Children. Acta Medica Philippina, 2020, 54, .	0.1	0
196	A global natural history study of Fibrodysplasia Ossificans Progressiva (FOP): 12-month outcomes. Endocrine Abstracts, 0, , .	0.0	0
197	OR29-05 A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. Journal of the Endocrine Society, 2020, 4, .	0.2	0
198	Compartment Syndrome of the Thigh in a Patient with Fibrodysplasia Ossificans Progressiva. Journal of Orthopaedic Case Reports, 2020, 10, 103-107.	0.1	0

#	Article	IF	Citations
199	P068â€ƒAbstract tin soldiers Global FOP patient search. Rheumatology, 2021, 60, .	1.9	0
200	Fibrodysplasia Ossificans Progressiva. , 0, , 211-236.		0